Conflicts of Interest. Chris McMahon, Paid consultant and clinical trial investigator to Pfizer, Icos Lilly, Bayer, GlaxoSmithKline, American Medical Systems, Johnson & Johnson.
Disorders of Orgasm and Ejaculation in Men
Article first published online: 3 AUG 2004
The Journal of Sexual Medicine
Volume 1, Issue 1, pages 58–65, July 2004
How to Cite
McMahon, C. G., Abdo, C., Incrocci, L., Perelman, M., Rowland, D., Waldinger, M. and Xin, Z. C. (2004), Disorders of Orgasm and Ejaculation in Men. Journal of Sexual Medicine, 1: 58–65. doi: 10.1111/j.1743-6109.2004.10109.x
- Issue published online: 3 AUG 2004
- Article first published online: 3 AUG 2004
- Premature Ejaculation;
- Retrograde Ejaculation;
- Inhibited Ejaculation;
- Selective Serotonon Re-Uptake Inhibitors;
Introduction. Ejaculatory/orgasmic disorders, common male sexual dysfunctions, include premature ejaculation, inhibited ejaculation, anejaculation, retrograde ejaculation and anorgasmia.
Aim. To provide recommendations/guidelines concerning state-of-the-art knowledge for management of ejaculation/orgasmic disorders in men.
Methods. An International Consultation in collaboration with the major urology and sexual medicine associations assembled over 200 multidisciplinary experts from 60 countries into 17 committees. Committee members established specific objectives and scopes for various male and female sexual medicine topics. The recommendations concerning state-of-the-art knowledge in the respective sexual medicine topic represent the opinion of experts from five continents developed in a process over a 2-year period. Concerning the Disorders of Ejaculation/Orgasm in Men Committee, there were nine experts from six countries.
Main Outcome Measure. Expert opinion was based on grading of evidence-based medical literature, widespread internal committee discussion, public presentation and debate.
Results. Premature ejaculation management is dependent upon etiology. When secondary to ED, etiology-specific treatment is employed. When lifelong, initial pharmacotherapy (SSRI, topical anesthesia, PDE5 inhibitors) is appropriate. When associated with psychogenic/relationship factors, behavioral therapy is indicated. When acquired, pharmacotherapy and/or behavioral therapies are preferred. Retrograde ejaculation, diagnosed with spermatozoa and fructose in centrifuged post-ejaculatory voided urine, is managed by education, patient reassurance, pharmacotherapy or bladder neck reconstruction. Men with anejaculation or anorgasmia have a biologic failure of emission and/or psychogenic inhibited ejaculation. Men with age-related penile hypoanesthesia should be educated, reassured and be instructed in revised sexual techniques which maximize arousal.
Conclusions. More research is needed in understanding management of men with ejaculation/orgasmic dysfunction.